These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
440 related articles for article (PubMed ID: 26988828)
1. [Comparison of clinical outcomes of patients with non-small cell lung cancer harboring different types of epidermal growth factor receptor sensitive mutations after first-line EGFR-TKI treatment]. Liu JJ; Zhang S; Wu CJ; Ma LX; Liu Y; Li H; Cui HX; Cheng Y Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):211-7. PubMed ID: 26988828 [TBL] [Abstract][Full Text] [Related]
2. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC. Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212). Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334 [TBL] [Abstract][Full Text] [Related]
4. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations. Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis. Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745 [TBL] [Abstract][Full Text] [Related]
6. Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer. Huang LT; Zhang SL; Han CB; Ma JT Lung Cancer; 2022 Apr; 166():9-16. PubMed ID: 35151115 [TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan. Chang JW; Huang CY; Fang YF; Chang CF; Yang CT; Kuo CS; Hsu PC; Wu CE Thorac Cancer; 2023 Jan; 14(1):12-23. PubMed ID: 36424878 [TBL] [Abstract][Full Text] [Related]
8. Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study. Zhou J; Qin H; Miao J; Liu R; Wang W Medicine (Baltimore); 2023 Jun; 102(26):e34110. PubMed ID: 37390279 [TBL] [Abstract][Full Text] [Related]
9. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types. Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803 [TBL] [Abstract][Full Text] [Related]
10. Comparison of therapeutic effects of EGFR-tyrosine kinase inhibitors on 19Del and L858R mutations in advanced lung adenocarcinoma and effect on cellular immune function. Zhou J; Ben S Thorac Cancer; 2018 Feb; 9(2):228-233. PubMed ID: 29222872 [TBL] [Abstract][Full Text] [Related]
11. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients. Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948 [TBL] [Abstract][Full Text] [Related]
12. Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M. Wang Y; Zheng R; Hu P; Zhang Z; Shen S; Li X BMC Cancer; 2021 Nov; 21(1):1215. PubMed ID: 34774017 [TBL] [Abstract][Full Text] [Related]
13. Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis. Wang H; Huang J; Yu X; Han S; Yan X; Sun S; Zhu X J Cancer Res Clin Oncol; 2014 Nov; 140(11):1901-9. PubMed ID: 24908327 [TBL] [Abstract][Full Text] [Related]
15. The efficacy of immune checkpoint inhibitors in advanced Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y Front Immunol; 2022; 13():975246. PubMed ID: 36159795 [TBL] [Abstract][Full Text] [Related]
16. Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non-small cell lung cancer harboring EGFR mutation. Kodama H; Kenmotsu H; Kawabata T; Notsu A; Yabe M; Nishioka N; Miyawaki E; Miyawaki T; Mamesaya N; Kobayashi H; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Takahashi T Cancer Med; 2021 Nov; 10(21):7503-7513. PubMed ID: 34587359 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China. Wang Y; Yuan X; Yang M; Shen Z; Chen H; He X; Ma Y; Ding L Pharmacology; 2021; 106(11-12):658-666. PubMed ID: 34673645 [TBL] [Abstract][Full Text] [Related]
18. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis. Sheng M; Wang F; Zhao Y; Li S; Wang X; Shou T; Luo Y; Tang W Eur J Clin Pharmacol; 2016 Jan; 72(1):1-11. PubMed ID: 26490356 [TBL] [Abstract][Full Text] [Related]
19. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China. Xu J; Jin B; Chu T; Dong X; Yang H; Zhang Y; Wu D; Lou Y; Zhang X; Wang H; Han B Lung Cancer; 2016 Jun; 96():87-92. PubMed ID: 27133756 [TBL] [Abstract][Full Text] [Related]
20. Traditional Chinese Medicine Prolongs Progression-Free Survival and Enhances Therapeutic Effects in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)Treated Non-Small-Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations. Tang M; Wang S; Zhao B; Wang W; Zhu Y; Hu L; Zhang X; Xiong S Med Sci Monit; 2019 Nov; 25():8430-8437. PubMed ID: 31704907 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]